Anticancer fusion protein comprising trail and a growth factor receptor inhibitor
A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an anti-angiogenic effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
1. A fusion protein comprising:
(i) domain (a) comprising a functional fragment of soluble human Tumour Necrosis Factor-Related Apoptosis Inducing Ligand (hTRAIL) protein sequence starting with an amino acid in a position not lower than hTRAIL95 and ending with the amino acid at position hTRAIL281, or a homolog of said functional fragment having at least 70% sequence identity; and
(ii) domain (b) comprising a sequence of an anti-angiogenic effector peptide, wherein said effector peptide is an inhibitor for growth factor receptor and is selected from the group of growth factor fragments consisting of a Vascular Endothelial Growth Factor (VEGF) fragment having the amino acid sequence set forth as SEQ ID NO: 17, a Platelet-Derived Growth Factor (PDGF) fragment having the amino acid sequence set forth as SEQ ID NO: 22, and an Epidermal Growth Factor (EGF) fragment having the amino acid sequence set forth as SEQ ID NO: 23;
wherein the sequence of domain (b) is attached at C-terminus or N-terminus of domain (a).
2. The fusion protein according to claim 1 , wherein domain (a) comprises the functional fragment of soluble hTRAIL protein sequence starting with an amino acid in a range from hTRAIL95 to hTRAIL121, inclusive.
3. The fusion protein according to claim 2 , wherein domain (a) is selected from the group consisting of hTRAIL95-281, hTRAIL119-281, hTRAIL120-281 and hTRAIL121-281.
4. The fusion protein according to claim 1 , wherein the fusion protein between domain (a) and domain (b) contains domain (c) comprising a protease cleavage site, selected from the group consisting of sequences recognized by metalloprotease MMP, a sequence recognized by urokinase uPA, or a combination thereof.
5. The fusion protein according to claim 4 , wherein the sequence recognized by metalloprotease MMP is SEQ ID NO: 24, SEQ ID NO: 55 or SEQ ID NO: 56, and the sequence recognized by urokinase uPA is SEQ ID NO: 25.
6. The fusion protein according to claim 5 , wherein the fusion protein between domains (a), (b), or (c) comprises additionally a glycine, glycine-serine or cysteine flexible steric linker or a combination thereof.
7. The fusion protein according to claim 1 , having an amino acid sequence selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO:4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48, and SEQ ID NO: 49.
8. A pharmaceutical composition, comprising as an active ingredient the fusion protein as defined in claim 7 , in combination with a pharmaceutically acceptable carrier.
9. A pharmaceutical composition, comprising as an active ingredient the fusion protein as defined in claim 1 , in combination with a pharmaceutically acceptable carrier.
10. A method of treatment of cancer in a mammal in a need thereof, comprising administering to the mammal an effective amount of the pharmaceutical composition as defined in claim 9 .
11. The method of claim 10 , wherein the mammal is a human.
12. The fusion protein of claim 1 , wherein domain (b) comprises a VEGF fragment having the amino acid sequence set forth as SEQ ID NO: 17.
13. The fusion protein of claim 1 , wherein domain (b) comprises a PDGF fragment having the amino acid sequence set forth as SEQ ID NO: 22.
14. The fusion protein of claim 1 , wherein domain (b) comprises an EGF fragment having the amino acid sequence set forth as SEQ ID NO: 23.